Anti-interleukin-2 receptor monoclonal antibody LO-Tact-1

Drug Profile

Anti-interleukin-2 receptor monoclonal antibody LO-Tact-1

Alternative Names: Anti-CD25 monoclonal antibody LO-Tact-1; Interleukin-2 receptor monoclonal antibody LO-Tact-1; LO-Tact-1

Latest Information Update: 02 Jul 1999

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Graft-versus-host disease

Most Recent Events

  • 02 Jul 1999 No-Development-Reported for Graft-versus-host disease in Belgium (IV-infusion)
  • 28 Aug 1996 A study has been added to the Transplant Rejection therapeutic trials section .
  • 20 Mar 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top